| Endometriosis
Myfembree vs Orilissa
Side-by-side clinical, coverage, and cost comparison for endometriosis.Deep comparison between: Myfembree vs Orilissa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrilissa has a higher rate of injection site reactions vs Myfembree based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orilissa but not Myfembree, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Myfembree
Orilissa
At A Glance
Oral
Daily
GnRH receptor antagonist
Oral
Once or twice daily
GnRH receptor antagonist
Indications
- Uterine Fibroids
- Menorrhagia
- Endometriosis
- Endometriosis
Dosing
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis 150 mg once daily for up to 24 months, taken orally at approximately the same time each day with or without food.
Endometriosis with dyspareunia Consider 200 mg twice daily for up to 6 months, taken orally.
Endometriosis with moderate hepatic impairment (Child-Pugh Class B) 150 mg once daily for up to 6 months; 200 mg twice daily is not recommended.
Contraindications
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
- Pregnancy (exposure early in pregnancy may increase risk of early pregnancy loss)
- Known osteoporosis (risk of further bone loss)
- Severe hepatic impairment (Child-Pugh C)
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
- Known hypersensitivity reaction to elagolix or any inactive component (including anaphylaxis and angioedema)
Adverse Reactions
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Most common (>=5%) Hot flush, headache, nausea, insomnia, mood altered/mood swings, amenorrhea, depressed mood/depression, anxiety, arthralgia
Serious Bone loss, change in menstrual bleeding pattern, suicidal ideation and suicidal behavior, exacerbation of mood disorders, hepatic transaminase elevations
Postmarketing Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria
Pharmacology
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
GnRH receptor antagonist; elagolix competitively binds GnRH receptors in the pituitary gland, causing dose-dependent suppression of LH and FSH and reducing ovarian estradiol and progesterone concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
Orilissa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Orilissa
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (5/8) · Qty limit (7/8)
Humana
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Orilissa
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MyfembreeView full Myfembree profile
OrilissaView full Orilissa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.